Don't Be Fooled: Brand Drugs Cut Prices More Than Generics

Current health policy discussions around the globe are heavily focused on the ever-increasing cost of healthcare and our ability to afford it in the future. They frequently focus on the topic of the relative value of more expensive brand name drugs, first exclusively sold on patent by the firms that develop them, versus cheaper generics or bio-similar drugs, which are allowed to enter the market once the patent for the branded drug has expired.